Trial reportContemporary clinical trials2017
Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Trial report in Contemporary clinical trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02867124 (Long-acting Naltrexone for Pre-release Prisoners), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-acting Naltrexone for Pre-release Prisoners: A Randomized Trial of Mobile Treatment
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Sustained-release naltrexone for opioid dependence.The Cochrane database of systematic reviews · 2025Pooled it
- Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review.Addiction (Abingdon, England) · 2025Pooled it
- Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.Drug and alcohol dependence · 2019Trial
- Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural Appalachia.Journal of community psychology · 2024Article
- Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review.Journal of substance use and addiction treatment · 2024Article
- Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review.Frontiers in public health · 2024Review
- Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.Health affairs (Project Hope) · 2023Article
- Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.International journal of qualitative studies on health and well-being · 2022Article
- Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.BMC public health · 2022Article
- Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes.Campbell systematic reviews · 2022Article
- Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD.Health & justice · 2021Article
- The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study.Drug and alcohol dependence · 2020Article
- Interventions for drug-using offenders with co-occurring mental health problems.The Cochrane database of systematic reviews · 2019Review
- Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.Health affairs (Project Hope) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundExtended-release naltrexone (XR-NTX), is an effective treatment for opioid use disorder but is rarely initiated in US prisons or with criminal justice populations. Mobile treatment for chronic diseases has been implemented in a variety of settings. Mobile treatment may provide an opportunity to expand outreach to parolees to surmount barriers to traditional clinic treatment.
methodsMale and female prisoners (240) with pre-incarceration histories of opioid use disorder who are within one month of release from prison will be enrolled in this randomized clinical trial. Participants are randomized to one of two study arms: 1) [XR-NTX-OTx] One injection of long-acting naltrexone in prison, followed by 6 monthly injections post-release at a community opioid treatment program; or 2) [XR-NTX+ MMTx] One injection of long-acting naltrexone in prison followed by 6 monthly injections post-release at the patient's place of residence utilizing mobile medical treatment. The primary outcomes are: treatment adherence; opioid use; criminal activity; re-arrest; reincarceration; and HIV risk-behaviors.
resultsWe describe the background and rationale for the study, its aims, hypotheses, and study design.
conclusionsThe use of long-acting injectable naltrexone may be a promising form of treatment for pre-release prisoners. Finally, as many individuals in the criminal justice system drop out of treatment, this study will assess whether treatment at their place of residence will improve adherence and positively affect treatment outcomes. ClinicalTrials.gov: NCT02867124.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.